Participated · Series A · Mar 2024

VIE (formerly VIE STYLE) builds earbud-type EEG devices that use the eartip as an electrode to collect brainwaves with the simplicity of standard earphones. Its flagship hardware includes VIE ZONE, an earphone-form wearable EEG, and VIE CHILL, a high-performance wireless earphone that analyzes users' brainwaves and generates music to guide ideal brain states. The company also offers a brainwave-music app, VIE Tunes, which reached 40,000 downloads within three months of launch. VIE is pursuing both consumer expansion and applied use in medical, healthcare, and sensing contexts, and is developing industry-specific products through partnerships. The firm says it will continue investing in research and business development to accelerate technology and hardware work and to address social challenges. Current product strategy blends hardware, neurofeedback software, and generated "neuromusic" to create measurable wellbeing experiences.

Participated · Series B · Apr 2020

COMPASS Pathways develops COMP360, a proprietary synthetic psilocybin formulation delivered with psychological support to treat individuals who do not respond to current therapies. The company has earned FDA Breakthrough Therapy status and the UK ILAP designation for COMP360 in treatment‑resistant depression (TRD). It completed a phase 2b study showing significant symptom improvement with a 25mg dose and has launched the largest‑ever randomized, controlled, double‑blind phase 3 programme for TRD. COMPASS is also running phase 2 trials in PTSD and anorexia nervosa and investing in digital technology to support its therapy. The company announced a large private financing to support its clinical programmes, commercial planning and research through roughly late 2025. Compass Pathways is a London-based mental health care company focused on developing psilocybin therapy for treatment-resistant depression. Its lead program is a large-scale psilocybin therapy clinical trial being conducted at 20 sites across nine countries in Europe and North America. The company received FDA Breakthrough Therapy designation for its psilocybin therapy program in 2018. Compass intends to use the Series B proceeds to expand its lead program, support research into additional indications for psilocybin therapy, advance its preclinical pipeline, develop digital technologies, and establish new academic and clinical research partnerships. Leadership includes CEO and co-founder George Goldsmith and President, Chief Business Officer and co-founder Lars Wilde.

Led · Equity · Oct 2018

Proteus Digital Health develops digital medicines combining an ingestible sensor, a wearable patch, mobile apps and data analytics to provide objective summaries of drug ingestion and physiologic data. Its flagship product, ABILIFY MYCITE, is an FDA‑approved drug‑device combination that pairs aripiprazole tablets embedded with an ingestible event marker, the MYCITE Patch, and a companion app and dashboards. The company holds more than 450 issued patents and has regulatory clearances in the U.S., European Union and China. Proteus plans to expand its portfolio by integrating its sensors with other therapies, develop next‑generation product features and sensor capabilities, and pursue broader commercialization and software integration. The expanded collaboration with Otsuka dedicates joint teams for commercial development, software integration and standardization, manufacturing and supply‑chain coordination. Proteus is privately held by investors that include Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka and ON Semiconductor. Proteus Discover combines an FDA-cleared ingestible sensor co-encapsulated with medications, a small wearable patch, patient and provider applications, and data analytics to record dosing times and physiologic metrics such as heart rate and activity. The ingestible sensor is described as the size of a grain of sand and, when taken, signals the patch which logs medication-taking and physiologic responses. The company currently markets a co-encapsulation model and is pursuing further FDA review for a panel of Digital Medicines with the sensor directly integrated into medications. Proteus plans to drive increased adoption of Proteus Discover by partnering with health system customers to demonstrate outcomes achievable with Digital Medicines. The company says the new capital will strengthen its balance sheet and provide funding to expand its Digital Medicine platform and commercial efforts. Proteus Digital Health develops digital medicines that integrate pharmaceuticals with ingestible sensors, wearable devices, mobile and cloud computing to provide the digital health feedback system. Its core products include ingestible sensors and wearable devices; Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for those devices. The company says its platform provides an unprecedented view into patients’ health choices and physiologic responses and enables new information-based business models. Proteus is privately held and headquartered in Redwood City, Calif., and is funded by institutional and strategic investors including Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, Oracle and ON Semiconductor. The company completed a financing process in which it announced a $120 million first part on June 2 and then completed a second closing of its Series G financing raising over $172 million. Proteus intends to use the funding to advance manufacturing and commercialization of its digital medicines. Proteus Digital Health develops digital medicine products that combine tiny ingestible sensors, wearable sensor devices, and a digital health feedback system. The company's core product embeds a tiny sensor in pharmaceuticals that communicates medication-taking behavior and how a patient’s body is responding. Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable sensor devices. Led by CEO Andrew Thompson, the company is working to define an innovative category of products, services and data systems called Digital Medicines. Financially, Proteus secured a $31.6M debt financing package whose proceeds will be used for working capital growth. The company is funded by investors including Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, Oracle, ON Semiconductor and others. Proteus Digital Health develops Digital Medicines built around ingestible sensors and a digital health feedback system that communicates medication-taking behavior and physiologic response. Its core product set includes ingestible sensors and wearable devices plus data systems intended to enable new care paradigms and information-based business models. Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable and ingestible sensor devices. The company says it aims to embed its technology into established products and services to accelerate its mission and change healthcare. Proteus completed a second closing of its Series F financing, raising $62.5 million in total. It is privately held and funded by investors including Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, Oracle, ON Semiconductor and others; the recent financing added corporate investor Oracle alongside Otsuka, Novartis and Sino Portfolio.

Led · Series D · Apr 2015

ReCor Medical develops the Paradise ultrasound renal denervation (RDN) system and is based in Palo Alto and Amsterdam. Paradise has CE Mark approval in the European Union and has been tested in three clinical trials involving more than 200 patients. The company emphasizes its ultrasound approach may offer advantages over radiofrequency systems by providing active vessel protection and 360° energy delivery. ReCor plans to pursue a U.S. clinical trial of Paradise and has engaged with the FDA on study design. Management stated they aim to finalize the clinical study design and begin patient enrollment in the second half of 2015. The recent funding is intended to support those clinical activities.

Participated · Equity · Nov 2008

GangaGen is developing a program called Klebicin in collaboration with CARB‑X. CARB‑X awarded the company a US$2.1 million grant to support lead optimization of the Klebicin program. The grant was awarded based on GangaGen's successful accomplishment of agreed milestones within the previously announced CARB‑X collaboration. The funding is explicitly described as a grant from CARB‑X to advance lead optimization work. No revenue, user, or other operating metrics are reported in the article. GangaGen's immediate focus, as reported, is progressing the Klebicin program through lead optimization funded by this CARB‑X award. GangaGen is a Palo Alto–based biotech developing treatments for bacterial infections, with a focus on antibiotic-resistant strains such as Staphylococcus. The company targets medical, veterinary and agricultural markets. Its pipeline currently includes a preventative prophylactic and a topical treatment for wounds and burns. GangaGen raised $5.4 million in a fifth-round financing to advance those programs. Investors in this round are ATEL Ventures, Otsuka Pharmaceuticals and ICF Ltd. GangaGen is a San Francisco, Calif. biotech company working on bacteriophages, viruses that infect and destroy bacteria. The company is developing treatments for antibiotic-resistant bacterial infections, including pneumonia and MRSA. GangaGen raised $1.8 million to develop those treatments. This is the company’s first funding round. ATEL Ventures made the investment.